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Background: Recent studies indicated that a synthetic oligonucleotide containing un-methylated CpG
oligodeoxynucleotides (CpG-ODN) has a potential function for cancer therapy. In this study, we evaluated the
chemosensitizing effects of CpG-ODN in 5-fluorouracil (5-FU)-treated HepG2 human hepatoma cells.
Methods: Cell viability assay were utilized to evaluate the direct cytotoxicity of CpG-ODN in the presence or
absence of 5-FU in HepG2 cells, and apoptosis as well as cell-cycle was examined by flow cytometry analysis. The
mRNA expression of Bcl-2, Livin and Survivin within HepG2 cells treated with CpG-ODN and/or 5-FU were analyzed
by Real Time PCR assay in vitro.
Results: CpG-ODN in combination with 5-FU could decrease cell viability, increase apoptosis and further induce
HepG2 cells cycle arrest at S phase when compared with CpG-ODN or 5-FU. CpG-ODN or 5-FU could down-
regulate the mRNA expression of Bcl-2 within HepG2 cells. The mRNA expression of Livin and Survivin decreased in
cells treated with CpG-ODN alone but increased in cells treated with 5-FU alone. However, CpG-ODN in
combination with 5-FU could down-regulate the mRNA expression of Livin and Survivin within HepG2 cells.
Conclusions: Our finding demonstrated that CpG-ODN enhanced the chemosentivity of 5-FU in HepG2 human
hepatoma cells at least in part by down-regulating the expression of Livin and Survivin, leading to apoptosis and
further inducing cell cycle arrest at S phase. Therefore, CpG-ODN may be a potential candidate as chemosensitizer
for human hepatocellular carcinoma.
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Hepatocellular carcinoma (HCC) is the main type of liver
cancer and the second leading cause of cancer-related
deaths worldwide [1]. It is well known that HCC is one of
the malignant tumors with poor chemosensitivity to anti-
cancer agents [2]. To date, the combination therapy with
chemotherapeutic agents and immunostimulators, such as
5-fluorouracil (5-FU) and IFN, has been found to be effect-
ive in enhancing the HCC-inhibitory effect of chemother-
apy [3,4]. Sakabe, T., et al. found some genes that are* Correspondence: mminjie@163.com
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reproduction in any medium, provided the orinvolved in chemosensitizing the effects of 5-FU and IFN-
α/5-FU on HCC cells [5]. Previous study demonstrated that
hepatocellular carcinoma (HCC) has high mortality partly
due to acquiring drug resistance during chemotherapy
treatment [6]. Acquired resistance to 5-fluorouracil (5-FU)
is a serious therapeutic obstacle in advanced hepatocellular
carcinoma (HCC) patients, but chemosensitizer can partly
reverse 5-FU resistance in HCC cells [7]. Therefore, there is
an urgent need for the development of a chemosensitizer
to increase the sensitivity of tumor cells to chemotherapy
within normal dosage.
Recently, a rapid accumulating evidence demonstrated
that CpG-ODN have been developed to stimulate the in-
nate immune response in various diseases through thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(TLR9) [8], which are mainly expressed on immune cell
[9], are also widely expressed on various tumor cells, in-
cluding human HCC cells [10]. Previous studies have
showed that CpG-ODN can mediate anti-tumor effects
on cancer cells due to its direct or indirect effects by in-
ducing release of cytokines, and enhancing immune re-
sponse [11]. Meanwhile, recent studies suggested that
CpG-ODN may be considered as a potential chemosen-
sitizer with weak side effects, such CpG-ODN 1826
[12,13] Clinical studies have also documented that CpG-
ODN in combination with chemotherapy cannot only
increase the treatment benefit of patients ,but also make
patients with well tolerated [14,15]. Although a previous
study had demonstrated the benefits of CpG-ODN for
HCC treatment [16], the direct cytotoxicity of CpG-
ODN against HCC cells and the potential mechanism
are not clear.
In our study, we investigated the chemosensitivity of
CpG-ODN in HepG2 human hepatoma cells, the HepG2
cells were cultured in vitro, and the cell proliferation, apop-
tosis, cell cycle and the antiapoptotic factors were tested.
The possible molecular mechanisms were investigated.
Results
CpG-ODN in combination with 5-FU decreases cell
viability in HepG2 cells
Previous studies showed that TLR9 is expressed in hu-
man lung cancer A549 cells [17] and human hepatoma
HepG2 cells [10]. TLR9 expression and function in BEL-
7402 cells, belong to the human hepatoma cell lines, are
not reported. The expression of functional active TLR9
in human malignant tumors might affect treatment ap-
proaches using CpG-ODN. To evaluate the cytotoxicity
of CpG-ODN on HepG2 cells, BEL-7402 cells and A549
cells, cells were incubated with five gradient concentra-
tion ranging from 0.25 to 25 μM for 48 h. The viability
was determined using CellTiter 96®Aqueous One Solu-
tion Cell Proliferation Assay (MTS). The results showed
that CpG-ODN significantly decreased the viability of
HepG2 cells in a dose-dependent manner. However,
CpG-ODN had no effect on the viability of BEL-7402
cells and A549 cells (Figure 1A). These findings indi-
cated that HepG2 cells, but not BEL-7402 cells and
A549 cells, are sensitive to CpG-ODN. Taking into ac-
count the high inhibition of CpG-ODN on HepG2 cells,
and it was selected and used in the subsequent
experiments.
Tanaka, J. et al. [10] found that HepG2 cell following
incubation with the type C CpG oligonucleotide (ODN
M362: 5′-TCGTCGTCGTTCGAACGACGTTGAT-3′)
could promote cell proliferation and survival in human
hepatocellular carcinomas. Herein, we compared the
cytotoxicity of non-CpG-ODN,CpG-ODN and ODNM362 toward HepG2 cells, cells were treated with non-
CpG-ODN, CpG-ODN or ODN M362 at five concentra-
tion ranging from 0.25 to 25 μM for the indicated time.
The result showed that CpG-ODN significantly reduced
the viability of HepG2 cells in time and dose-dependent
manner (Figure 1B). However, non-CpG-ODN and
ODN M362 didn’t have direct cytotoxicity toward
HepG2 cells (Figure 1C). The results showed that CpG-
ODN, but not ODN M362 and non-CpG-ODN, can dir-
ectly mediate cytotoxicity toward HepG2 cells.
To evaluate the inhibition effect of 5-FU treatment on
HepG2 cells, the proliferation of cells following treated with
5-FU at designated concentration(2.5,5,7.5,15,25 μg/ml)
was detected using MTS assay after incubation for another
24 h、48 h and 72 h. The result showed that 5-FU alone
inhibited the proliferation of HepG2 cells in time
dependent manner (Figure 1D). In order to evaluate the
synergistic effect of CpG-ODN and 5-FU on HepG2 cells,
cells following treated with CpG-ODN in presence or ab-
sence of 5-FU were carried out in MTS assay. As illustrated
in Figure 1E, CpG-ODN in combination with 5-FU could
decrease cell viability when compared with CpG-ODN or
5-FU alone. To further determine if CpG-ODN can en-
hance the chemosensitivity of 5-FU-treated HepG2 cells ,
the cells treated with a rang of doses of 5-FU in the pres-
ence and absence of 4 μM CpG-ODN or non-CpG-ODN
for 24 h. Figure 1F showed that treatment with a series of
doses of 5-FU in the presence of CpG-ODN( 4 μM) in-
creased the inhibition compared with 5-FU and/or non-
CpG-ODN treated groups, further supporting the synergis-
tic effect.
CpG-ODN in combination with 5-FU affects the cell
morphology of HepG2 cells
In order to make sure whether CpG-ODN and/or 5-FU
treatment could affect the cell morphology of HepG2
cells, the morphology of cells were observed in the
inverted microscope. The microscopic observations re-
vealed that the exposure of HepG2 cells in CpG-ODN in
combination with 5-FU for 48h displayed significant
morphology alterations. For 7.5μg/ml 5-FU and 2 μM
CpG-ODN groups, HepG2 cells had no obvious change.
For 4 μM CpG-ODN group, cells began to shrink and
the floating cells appeared in the culture medium. For
7.5 μg/ml 5-FU plus 2 μM or 4 μM CpG-ODN group,
most of the HepG2 cells lost contacted with the sur-
rounding cells and emerged more floating cells. Mean-
while, number of survival cells decreased significantly
when compared with the medium group (Figure 2A).
Nuclear stained with Hoechst 33258, revealed nuclear
chromatin condensation in the CpG-ODN and 5-FU
alone or together treated cells, which was typical of
apoptotic cells. In 7.5 μg/ml 5-FU plus 2 μM or 4 μM
CpG-ODN group, the change is more obviously, while
Figure 1 Effect of CpG-ODN and/or 5-FU treatment on the cell viability in vitro. A: The cell viability of HepG2 cells, BEL-7402 cells and A549
cells treated with indicated concentration of CpG-ODN for 48 h in MTS assay, cell viability was expressed as the percentage of control cells
(medium). B: The cell viability of HepG2 cells treated with indicated concentration of CpG-ODN for indicated time in MTS assay, cell viability was
then quantified as described above. C: The cell viability of HepG2 cells treated with indicated concentration of non-CpG-ODN and ODN M362 for
48 h in MTS assay, cell viability was then quantified as described above. D: HepG2 cells were treated with indicated concentration of 5-FU for
indicated time in MTS assay, results were presented as the inhibitory ratio of 5-FU treated HepG2 cells. E: HepG2 cells treated with indicated
concentration of CpG-ODN, 5-FU or CpG-ODN in combination with 5-FU for indicated time, inhibition was then determined by the MTS assay. F:
The inhibitory ratio of HepG2 cells treated with a rang of 5-FU doses in the presence and absence of 4μM CpG-ODN or non-CpG-ODN for 24h. In
this figure, 5-FU, CpG(2) ,CpG(4) and non-CpG(4) represent that the concentration of 5-FU,CpG-ODN , CpG-ODN and non-CpG-ODN is 7.5 μg/ml ,
2 μM ,4 μM, 4 μM, respectively. All results shown were means ±SD from three independent experiments. *P<0.05, **P<0.01 and ***P<0.001
versus medium.
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escence (Figure 2B). The results of observation demon-
strated that CpG-ODN in combination with 5-FU could
affect the cell morphology of HepG2 cells and accelerate
cell death.
CpG-ODN in combination with 5-FU increases apoptosis
in HepG2 cells
We investigated that the CpG-ODN and/or 5-FU treat-
ment induced apoptosis using an Annexin V-FITC/PI
staining method. To evaluate whether CpG-ODN pro-
motes the chemosensitivity of 5-FU treated HepG2 cells
by up-regulating apoptosis, the apoptotic rate of HepG2
cells following treatment with CpG-ODN and 5-FU
alone or together for 48 h was detected. Fortunately, the
result showed that CpG-ODN in combination with 5-FU
treatment promoted apoptosis when compared with
CpG-ODN and 5-FU alone treatment (Figure 3A and B).
The finding suggested that CpG-ODN increased the
chemosensitivity of 5-FU-treated HepG2 cells by indu-
cing apoptosis.CpG-ODN in combination with 5-FU enhances cell cycle
arrest at the S phase in HepG2 cells
In order to examine whether the chemosensitivity of
CpG-ODN was related to cell cycle arrest, we next mea-
sured the cell cycle in HepG2 cells with flow cytometry
analysis and PI staining. Cells were incubated with CpG-
ODN and 5-FU alone or together as indicated concen-
tration for 48 h. As illustrated in Figure 4, the result
showed that CpG-ODN alone slightly induced cells cycle
arrest at G0/G1 phase and 5-FU alone could increase
cells to enter S phase. Moreover, CpG-ODN in combin-
ation with 5-FU treatment caused drastic accumulation
of cells in S-phase of the cell cycle, from 5-FU treatment
(69.34±2.11) to CpG-ODN in combination with 5-FU
treatment (83.20±2.40). The increase in S-phase cell
population was accompanied by a concomitant reduc-
tion of cells in G0/G1 and G2/M phase of cell cycle.
Therefore, CpG-ODN in combination with 5-FU could
further induce cells cycle arrest at S phase when com-
pared with 5-FU alone (Figure 4A and B). The result il-
lustrated that the chemosensitizing effect of CpG-ODN
Figure 2 Effect of CpG-ODN and/or 5-FU treatment on the cell morphology of HepG2 cells. A: Morphologic changes of HepG2 cells
treated with the indicated concentration of CpG-ODN and 5-FU alone or together for 48 h, compared with untreated cells (medium) (100X).
B: HepG2 cells treated with the indicated concentration of CpG-ODN and 5-FU alone or together for 48 h, then stained with Hoechst 33258
(400 X). Condensed and fragmented nuclei in cells were marked by arrow heads. In this figure, 5-FU, CpG(2) and CpG(4) represent that the
concentration of 5-FU, CpG-ODN and CpG-ODN is 7.5 μg/ml, 2 μM, 4 μM, respectively.
Liang et al. Cancer Cell International 2013, 13:106 Page 4 of 10
http://www.cancerci.com/content/13/1/106was related to further induce cell cycle arrest at the S
phase in 5-FU-treated HepG2 cells.
CpG-ODN in combination with 5-FU promotes the
chemosensitivity of 5-FU in HepG2 cells by down-
regulating the mRNA expression of Livin and Survivin
The antiapoptotic factors of Bcl-2 family which were re-
lated to the tumorigenesis and the sensitivity of chemo-
therapeutic drugs in tumor. Overexpression of Bcl-2
protein is common in many human cancers, and con-
tributes to resistance to chemotherapy [18]. In order to
test whether CpG-ODN or 5-FU could affect the expres-
sion of Bcl-2 within HepG2 cells, cells seeded in six-well
plates were treated with indicated concentration of
CpG-ODN or 5-FU. After 48 h, total RNA was extracted
for Bcl-2 mRNA expression using real-time PCR. The
results showed that CpG-ODN and 5-FU alone coulddecrease the mRNA expression of Bcl-2 within HepG2
cells (Figure 5A and B). These results showed that CpG-
ODN or 5-FU alone could induce the apoptosis of
HepG2 cells by down-regulating the expression of Bcl-2.
The Livin and Survivin protein, belong to the inhibi-
tors of apoptotic proteins (IAPs), were highly expressed
in tumor tissue but lowly in normal tissue, and the in-
duction of apoptosis was generally associated with
downregulation of Survivin and Livin within tumor cells
[19,20]. To examine whether CpG-ODN in combination
with 5-FU promotes the chemosensitivty of 5-FU in
HepG2 cells by regulating the expression of Livn and
Survivin, The real-time PCR was tested with the
same method as the above-mentioned. For the 5-FU
(7.5 μg/ml) group, the relative mRNA expression level of
Livin and Survivin is 4.98±2.94 and 1.59±0.42, respect-
ively. The results showed that 5-FU alone could up-
Figure 3 Effect of CpG-ODN and/or 5-FU treatment on apoptosis of HepG2 cells. A: The apoptosis was examined using annexin V-FITC/PI
staining and flow cytometry analysis. One representative flow cytrometry analysis of apoptosis in HepG2 cells. Fluorescence intensity for annexin
V/FITC is plotted on the x-axis, and PI is plotted on the y-axis. FITC-/PI-, FITC+/PI-, FITC+/PI+, FITC-/PI+ was regarded as living, early apoptotic, late
apoptotic and necrotic cells, respectively. B: The percentage of apoptotic cells examined by annexin V-FITC/PI staining and flow cytometry
analysis. Results are presented as mean ±SD of three separate experiments. ***P<0.001 versus medium. ###P<0.001 versus 5-FU. In this figure,
5-FU, CpG(2) and CpG(4) represent that the concentration of 5-FU, CpG-ODN and CpG-ODN is 7.5 μg/ml, 2 μM, 4 μM, respectively.
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CpG-ODN(2 μM) group, the relative mRNA expression
level of Livin and Survivin is 0.98±0.07 and 0.09±0.01,
respectively. For the CpG-ODN(4 μM) group, the relative
mRNA expression level of Livin and Survivin is 0.43±0.35
and 0.07±0.00, respectively. The results showed that
CpG-ODN alone could down-regulate the expression of
Livin and Survivin. For the 5-FU(7.5 g/ml)+CpG-ODN
(2 μM) group, the relative mRNA expression level of
Livin and Survivin is 0.38±0.07 and 0.52±0.07, respect-
ively. For the 5-FU(7.5 g/ml)+CpG-ODN(4 μM) group,
the relative mRNA expression level of Livin and Survi-
vin is 0.14±0.02 and 0.47±0.20, respectively. The results
showed that CpG-ODN in combination with 5-FU
could down-regulate the expression of Livin and Survi-
vin (Figure 5C and D). These clear results explained that
CpG-ODN in combination with 5-FU could promote
the chemosensitivity of 5-FU in HepG2 cells by down-regulating the expression of Livin and Survivin when
compared with 5-FU treatment.Discussion
Convincing evidence from both animal experiments and
pro-clinical studies suggest that CpG-ODN alone or in
combination with other therapeutics are useful for the
treatment of malignant tumors [21,22]. In the present
experiment, we firstly demonstrated that CpG-ODN
could significantly increase the chemosensitivity of 5-FU
in HepG2 human hepatoma cells in vitro. The mechan-
ism was related to CpG-ODN-mediated the expression
of anti-apoptotic factors within tumor cells, then indu-
cing apoptosis and cell cycle arrest at S phase. These
findings provide new understanding of CpG-ODN-
mediated direct cytotoxic effects and new insights into
the application of chemosensitizer.
Figure 4 Effect of CpG-ODN and/or 5-FU treatment on HepG2 cells cycle distribution. A: Cells were incubated with CpG-ODN and 5-FU
alone or together at indicated concentration for 48 h, and the cell cycle distribution was evaluated using PI staining and flow cytometry analysis.
One representative flow cytometry analysis of cell cycle distribution. B: The percentage of cells in G0/G1, S and G2/M phase is expressed as
mean ±SD of three independent experiments. *P<0.05,***P<0.001 versus medium. ###P<0.001 versus 5-FU. In this figure, 5-FU, CpG(2) and
CpG(4) represent that the concentration of 5-FU, CpG-ODN and CpG-ODN is 7.5 μg/ml , 2 μM , 4 μM , respectively.
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periments have confirmed that the activation of various
immune cells and the production of cytokines induced
by CpG-ODN have significant effect of anti-tumor
[23,24]. CpG-ODN is considered as a potential chemo-
sensitizer with unclear mechanism. Previous studies re-
ported that Peritumoral CpG-ODN1826 treatment
induces modulation of gene involved in DNA repair and
sensitizes cancers cells to DNA-damaging cisplatin treat-
ment in human IGROV-1 ovarian tumor cells [25], and
peritumoral injection of CpG-ODN1826 in combinationwith subcutaneous injection of 5-FU inhibit tumor
growth and reverse the immunosuppression caused by
the therapy 5-fluorouracil in murine hepatoma [26].
However, the direct cytotoxicity toward HepG2 cells is
not investigated in vitro. In our experiment, the results
demonstrated that CpG-ODN could significantly in-
crease the chemosensitivity of 5-FU in human hepatoma
HepG2 cells in vitro.
Apoptosis was thought to be the major reason of cell
death induced by chemosensitizer. Recent studies indicated
that stimulation of TLR9 with CpG-ODN enhanced
Figure 5 Effect of CpG-ODN and/or 5-FU treatment on anti-apoptotic factors within HepG2 cells. A and B: The cells seeded in six-well
plates were treated with the indicated concentration of CpG-ODN (A) or 5-FU (B). After 48 h, total RNA was extracted for Bcl-2 mRNA expression
using Real-time quantitative PCR. C and D: The cells seeded in six-well plates were treated with the indicated concentration of CpG-ODN and 5-
FU alone or together, the Livin(C) and Survivin(D) mRNA expression were analyzed using Real-time quantitative PCR analysis as described above.
Results are presented as mean ±SD of three separate experiments. *P<0.05, ***P<0.001 versus medium. #P<0.05, ##P<0.01, ###P<0.001 versus 5-FU.
In this figure, 5-FU, CpG(2) and CpG(4) represent that the concentration of 5-FU, CpG-ODN and CpG-ODN is 7.5 μg/ml, 2 μM, 4 μM, respectively.
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ODN M362 promotes cell proliferation and survival in hu-
man hepatocellular carcinomas [10]. So we compare the
direct cytotoxicity of CpG-ODN and ODN M362 toward
HepG2 cells, our results showed that CpG-ODN induced
significant inhibition of the survival of HepG2 cells, and
ODN M362 had not direct cytotoxicity toward HepG2 cells
(Figure 1). we next documented that apoptosis was respon-
sible for CpG-ODN and/or 5-FU induced cytotoxicity of
HepG2 cells using MTS assay, observation of cell morph-
ology, Hoechst 33258 staining, and annexin V-FITC
staining (Figures 1, 2 and 3), these results indicated that
CpG-ODN increased the chemosensitivity of 5-FU in
HepG2 cells by increasing apoptosis without the need for
immune system of host. Although many studies were fo-
cused on the immunotherapeutic applications of CpG-
ODN by modulating immune system of tumor-bearing
hosts [29,30], some recent data showed that direct cytotox-
icity against tumor cells is promising for therapy of different
malignancies [31,32]. These previous studies strongly sup-
ported our study, these results showed that CpG-ODNdirectly induced apoptosis and increased the chemosensi-
tivity of 5-FU in HepG2 human hepatoma cells.
Cell cycle arrest was thought to be another major rea-
son of cell death induced by anti-tumor drugs [33,34].
Fluorouracil (5-FU) is a pyrimidine analogue which is
transformed inside the cell into different cytotoxic me-
tabolites and then incorporates into DNA and RNA, fi-
nally inducing cell cycle arrest and apoptosis by
inhibiting the cell’s ability to synthesize DNA. It is an S-
phase specific drug and only active during certain cell
cycles. In this study, 7.5 μg/ml of 5-FU induced cell cycle
arrest at S phase, which was in line with previous study
[35]. Meanwhile, we found that 2 μM or 4 μM of CpG-
ODN in combination with 7.5 μg/ml of 5-FU could fur-
ther induce cells cycle arrest at S phase when compared
with 5-FU alone (Figure 4). These findings suggest that
CpG-ODN in combination with 5-FU induced apoptosis
by interrupting the transition of cell cycle from S phase
into G2/M phase, suggesting that the chemosensitizing
effect of CpG-ODN was related to cell cycle arrest at S
phase.
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to chemotherapeutic drugs and radiotherapy, while the
downregulation of Bcl-2 expression may promote apop-
totic response to anticancer drugs [36,37]. Real-time
quantitative PCR experiments showed that CpG-ODN
and 5-FU alone inhibited the expression of Bcl-2 within
HepG2 cells. Furthermore, CpG-ODN treatment sup-
pressed the expression of Bcl-2 in a dose-dependent
manner (Figure 5). These results suggested that the
apoptosis induced by CpG-ODN and 5-FU is related to
the downregulation of Bcl-2, but the exact molecular
mechanism needs further study.
Previous studies have demonstrated that the overex-
pression of inhibitors of apoptotic proteins (IAPs) was
resistant to the apoptosis induced by chemotherapy or
radiotherapy [19,38,39], and Livin and Survivin protein
belong to IAPs. Livin and Survivin produce anti-
apoptotic effects through a complex signaling pathway
[40,41]. Some studies have shown that overexpression of
Survivin or Livin was closely related to chemoresistance,
and inhibition of Survivin or Livin improved the sensi-
tivity of tumor to chemotherapy [42-44]. In present
study, our data showed that 5-FU alone could up-
regulate the expression of Livin and Survivin within
HepG2 cells (Figure 5). The result suggested that the ex-
pression of Livin and Survivin within HepG2 cells was
induced by chemotherapy drug 5-FU, thus resisted to
apoptosis induced by 5-FU. However, HepG2 cell follow-
ing treatment with CpG-ODN (2 μM or 4 μM) in the
presence or absence of 5-FU(7.5 μg/ml) could down-
regulate the expression of Livin and Survivin (Figure 5) .
These results suggested CpG-ODN could promote the
chemosentivity of 5-FU in HepG2 cells by down-
regulating the expression of Livin and Survivin within
HepG2 cells. The said results provided a new field of
view for the mechanism of chemosensitizing effect of
CpG-ODN, which was not reported previously.
In conclusion, our results demonstrated that CpG-
ODN possessed a chemosensitizing effect by down-
regulating the expression of anti-apoptotic factors in
HepG2 human hepatoma cells, leading to apoptosis and
further inducing cell cycle arrest at S phase when com-
pared with 5-FU treatment. Therefore, CpG-ODN may




CellTiter 96®AQueous One Solution Cell Proliferation
Assay was purchased from Promage (CA, USA). Propi-
dium iodide (PI) and Rnase A were purchased from
Sigma (NY, USA). Annexin V/FITC kit and Hoechst
Staining Kit were purchased from Beyotime (Jiangsu,
China). Trizol Reagent were purchased from Invitrogen(Carlsbad, CA, USA). M-MLV RTase cDNA Synthesis
kit and SYBR® Premix Ex Taq™II kit were purchased
from TaKaRa Biotechnology Co., Ltd. (Dalian, China). 5-
Fluorouracil was purchased from Sigma (NY, USA).
All the primers were synthesized by Sangon Biotech
Co., Ltd (Shanghai, China). CpG-ODN contains a total
of 72 bases (5′-AACGTTGTCGTCGACGTCGTCGT-
CAGGCCTGACGTTATCG ATGGCGTTGTCGTCAAC
GTTGTCGTTAACGTT-3′). CpG-ODN, non-CpG-OD
N (a convers- ed CG sequence of CpG-ODN) and ODN
M362 (5′-TCGTCGTCGTTCGAACGACGTTGAT-3′)
were synthesized by Sangon Biotech Co., Ltd (Shanghai,
China). CG dinucleotides were indicated with underline.
All oligodeoxynucleotides used in the experiments were
in phosphorothioate backbone which was used to reduce
susceptibility of the ODN to DNase digestion, thereby
significantly prolonging its half-time in vitro. The oligo-
deoxynucleotides were dissolved with sterilized double
distilled water.
Cells culture
Human hepatoma HepG2 cells and BEL-7402 cells, hu-
man lung cancer A549 cells were cultured in 1640’s
medium (Hangzhou Evergreen Biological Engineering
Company, China) supplemented with 10% fetal bovine
serum(FBS) and antibiotics (100 U/ml penicillin and
100 μg /ml streptomycin) in a 5% CO2 atmosphere at
37°C. Endotoxin levels in cell culture media and super-
natants were undetectable(<1 ng/ml) as assessed by Lim-
ulus assay.
Cell viability assay
Cells (2×103/100 μl) were seeded in 96-well plates and
treated on the following day with indicated concentra-
tion of CpG-ODN, 5-FU or CpG-ODN in combination
with 5-FU. Cell viability was analyzed using CellTiter
96®AQueous One Solution Cell Proliferation Assay
(Promage) according to the manufacture’s instructions,
and optical density (OD) was read at 490 nm on a
microplate reader (Bio-Rad, California, USA). The
Viability(%) was calculated according to the following
equation: Viability(%)=(OD treated/ OD medium)×100%.
The inhibition rate was calculated according to the
following equation: Inhibition rate(%)=(1- OD treated/
OD control)×100%.
Cell morphology
Cells (1×105/2 ml) were seeded in 6-well plates and
grown for 24 h in order to attach to the surface of the
plates completely. They were treated with indicated con-
centrations of CpG-ODN, 5-FU or CpG-ODN in com-
bination with 5-FU. After incubation for another 48 h,
Cell morphology was photographed by the inverted
green light microscope (Olympus, Tokyo, Japan).
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the cells were rinsed PBS and stained using Hoechst Stain-
ing Kit according to the manufacture’s instructions. Stained
nuclei were visualized under UV excitation and photo-
graphed using an Olympus fluorescence microscopy
(Olympus, Tokyo, Japan).
Apoptosis assay
Cells (1×105/2 ml) were seeded in 6-well plates and
treated on the following day with indicated concentra-
tions of CpG-ODN, 5-FU or CpG-ODN in combination
with 5-FU. After incubation for another 48 h, cells were
trypsinized, washed with PBS, and stained using an
Annexin V/FITC kit according to the manufacture’s in-
structions. Apoptosis was detected using a COULTER
Epics xL Flow cytometer (Beckmam Coulter, CA, USA)
within 1h after staining. Ten thousand events were eval-
uated for each sample. Data were analyzed using FCS
Express Version 3 (De Novo Software, Canada).
Cell-cycle phase distribution assay
Cells (1×105/2 ml) were seeded in 6-well plates and
treated on the following day with indicated concentra-
tions of CpG-ODN, 5-FU or CpG-ODN in combination
with 5-FU. After incubation for another 48 h, adherent
and floating cells were collected and fixed in ice-cold
ethanol (70% in ddH2O) at 4°C overnight. The cells were
concentrated by removing ethanol and treated with
0.01% Dnase-free RNase A for 10 min at 37°C. Cellular
DNA was stained with 0.02% propidium iodide (PI) for
30 min at 4°C in the dark. Cell cycle distribution was de-
tected with FCM on a COULTER Epics xL flow cyt-
ometer (Beckmam Coulter, CA, USA). Ten thousand
events were evaluated for each sample and the percent-
age of cells at specific phases was analyzed using ModFit
LT software (Verity Software House, USA).
Real Time PCR assay
Cells (1×105/2 ml) were seeded in 6-well plates and
treated on the following day with indicated concentra-
tion of CpG-ODN, 5-FU or CpG-ODN in combination
with 5-FU. After incubation for another 48 h, total RNA
was extracted using a Trizol reagent and then reversely
transcribed into cDNA. The transcribed cDNA template
was mixed with SYBR® Premix Ex Taq™ II kit and the
following primers: Bcl-2, forward, 5′-CTTCGCCGA-
GATGTCCAGCCA-3′, reverse, 5′- CGCTCTCCACA
CACA TGACCC-3′; Livin, forward, 5′-TCTGAGG
AGTTGCGTCTGG-3′, reverse, 5′-GCACCTCACCT
TG TCCTGAT-3′; Survivin, forward, 5′-GACCACCG-
CATCTCTACATTC-3′, reverse, 5′-AAGTCT GGCTCG
TTCTCAGTG-3′; β-actin, forward, 5′-TGACGTGGA-
CATCCGCAAAG-3′, reverse, 5′-CTGGAAGGTGCA-
CAGAGAGG-3′. Real-time PCR was performed using aBio-Rad iQ5 quantitative PCR instrument (Bio-Rad, USA)
with three-step Mothod as follows: Pre-denature at 95°C
for 300s (1 cycle), denature at 95°C for 30s→anneal at
60°C for 20s →extend at 72°C for 45s(40 cycles), and an
additional extension at 72°C for 7 min. Dissociation
curve analysis was performed to see if there was any
bimodal dissociation curve or abnormal amplification
plot. For each sample, mRNA expression levels for spe-
cific transcripts were normalized to the amount of
β-actin and 2-△△Ct method was used to analyze the gene-
expression data.
Statistical analysis
Date was presented as mean ± standard deviation (SD).
One-way ANOVA was used to test the differences be-
tween the treated and the control groups, followed by
Tukey’s multiple comparisons. Differences with the p
value less than 0.05 were considered as statistically
significant.
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